Jubilant Pharmova Ltd - Stock Valuation and Financial Performance

BSE: 530019 | NSE: JUBLPHARMA | Pharmaceuticals & Drugs | Small Cap

Jubilant Pharmova Share Price

648.45 -0.60 -0.09%
as on 12-Apr'24 10:20

DeciZen - make an informed investing decision on Jubilant Pharmova

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Jubilant Pharmova stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
10,178.9 Cr.
52-wk low:
52-wk high:

Is Jubilant Pharmova Ltd an attractive stock to invest in?

1. Is Jubilant Pharmova Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Jubilant Pharmova Ltd is a below average quality company.

2. Is Jubilant Pharmova Ltd undervalued or overvalued?

The key valuation ratios of Jubilant Pharmova Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Jubilant Pharmova Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Jubilant Pharmova Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Jubilant Pharmova:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jubilant Pharmova Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 5.2%4%5.4%5.3%9.5%6.6%9.8%9%4.1%2.3%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,5633,1762,6562,4913,3063,4393,1402,710726810743
Sales YoY Gr.--10.9%-16.4%-6.2%32.7%4%-8.7%-13.7%-73.2%11.6%-
YoY Gr.--69.8%289.4%0.2%234.6%-35.7%99.4%-34.6%-62%-39.8%-
BVPS (₹) 112.2122.1126.3128.2141.2146.9163.780.5153.1151.4146.8
Adj Net
Cash Flow from Ops. 549286164419558182317608-3.6-65.1-
Debt/CF from Ops. 68114.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -15.2%-24.5%-36.3%11.6%
Adj EPS -3.1%-28.1%-46.9%-39.8%
Share Price 14.1% -1.3% -4.3% 113%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -36.34%

Net Profit has been subdued in last 3 years -46.92%

Sales growth is not so good in last 4 quarters at -8.46%

Latest Financials - Jubilant Pharmova Ltd.

Standalone Consolidated
TTM EPS (₹) -2 2.4
TTM Sales (₹ Cr.) 743 6,559
BVPS (₹.) 146.8 343
Reserves (₹ Cr.) 2,322 5,448
P/BV 4.35 1.86
PE 0.00 268.86
From the Market
52 Week Low / High (₹) 299.30 / 666.00
All Time Low / High (₹) 3.51 / 1046.75
Market Cap (₹ Cr.) 10,179
Equity (₹ Cr.) 15.9
Face Value (₹) 1
Industry PE 48

Management X-Ray of Jubilant Pharmova:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Jubilant Pharmova

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 3,0842,8942,3442,1732,7673,1182,7692,282719807
Manufacturing Costs617573513475568617640499103125
Material Costs1,9821,9361,4531,3101,7712,0531,6841,450332415
Employee Cost 298241216226264266265221164167
Other Costs 186145162162163183179113121100
Operating Profit 47928231231853932137142763
Operating Profit Margin (%) 13.5%8.9%11.8%12.8%16.3%9.3%11.8%15.8%0.9%0.4%
Other Income 301066252467817348126138
Interest 2852332011741351291361021119
Depreciation 175107878183861071003743
Exceptional Items -2271980000-2000
Profit Before Tax -178246861153681832992738579
Tax -8541133510436-2259429
Profit After Tax -9320573792631483212148050
PAT Margin (%) -2.6%6.5%2.7%3.2%8.0%4.3%10.2%7.9%11.1%6.2%
Adjusted EPS (₹)-
Dividend Payout Ratio (%)-50%23%65%60%18%49%25%37%99%160%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 1,7331,9452,0142,0422,2492,3402,6071,2822,4392,411
Share Capital 15161616161616161616
Reserves 1,7171,9291,9982,0262,2332,3242,5911,2672,4232,395
Minority Interest0000000000
Long Term Debt1,1411,7391,1151,3871,0591,1401,328420174174
Short Term Debt1,097340454177191463623730128
Trade Payables59950836448774959661916159164
Others Liabilities 2,0807093592883763252575389115
Total Liabilities 6,6515,2414,3064,3824,6254,8645,4331,8452,8602,991

Fixed Assets

Gross Block3,2432,3031,5021,5871,6851,8222,288149867956
Accumulated Depreciation1,0928578616624733142422230269
Net Fixed Assets2,1511,4461,4151,4211,4381,4911,865127637687
CWIP 2422036651152845903547
Investments 2,0061,7661,7091,7101,7061,7641,7641,6461,6461,657
Trade Receivables5303193413864944814250131189
Cash Equivalents 17913741773835258402311
Others Assets8101,037288269248317406316687
Total Assets 6,6515,2414,3064,3824,6254,8645,4331,8452,8602,991

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 549286164419558182317608-4-65
PBT -68246861153681832992738579
Adjustment 60659260230207159103196-49-35
Changes in Working Capital 1218-1688042-112-65181-3-92
Tax Paid -1-38-14-5-58-49-20-43-19-17
Cash Flow From Investing Activity -1941,319522-43-127-285-1981789331
Capex -151-79-68-103-141-281-197-92-37-59
Net Investments 090641300001290-9
Others -434921776014-4-114213098
Cash Flow From Financing Activity -361-1,647-784-338-47085-41-782-10723
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -170-301-520-156-2860-160-13600
Interest Paid -284-245-201-170-138-134-147-102-11-18
Dividend Paid -55-54-51-53-55-56-153-1-80-80
Others 148-1,048-13419275419-542-16121
Net Cash Flow -6-42-9838-40-18785-18-12
ROE (%)-
ROCE (%)2.1110.357.137.6413.578.110.111.824.363.67
Asset Turnover Ratio0.560.560.580.60.740.720.610.740.310.28
PAT to CFO Conversion(x)N/A1.
Working Capital Days
Receivable Days4647435148525306672
Inventory Days666865655757670163143
Payable Days1031041101191271201328096142

Jubilant Pharmova Ltd Stock News

Jubilant Pharmova Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Jubilant Pharmova on 12-Apr-2024 10:20 is ₹648.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 10:20 the market cap of Jubilant Pharmova stood at ₹10,178.9.
The latest P/E ratio of Jubilant Pharmova as of 12-Apr-2024 10:20 is 0.00.
The latest P/B ratio of Jubilant Pharmova as of 12-Apr-2024 10:20 is 4.35.
The 52-week high of Jubilant Pharmova is ₹666.0 and the 52-week low is ₹299.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jubilant Pharmova is ₹742.9 ( Cr.) .

About Jubilant Pharmova Ltd

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

  • Pharmaceuticals
  • Life Science Ingredients
  • Drug Discovery & Development Solutions
  • India Branded Pharmaceuticals



  • NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
  • Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.


  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.


  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
  • BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.


  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.


  • Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.


  • Social Entrepreneur of the Year (SEOY)-India Award 2017.
  • Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
  • ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.